Literature DB >> 22023676

Variable selection for qualitative interactions in personalized medicine while controlling the family-wise error rate.

Lacey Gunter1, Ji Zhu, Susan Murphy.   

Abstract

For many years, subset analysis has been a popular topic for the biostatistics and clinical trials literature. In more recent years, the discussion has focused on finding subsets of genomes which play a role in the effect of treatment, often referred to as stratified or personalized medicine. Though highly sought after, methods for detecting subsets with altering treatment effects are limited and lacking in power. In this article we discuss variable selection for qualitative interactions with the aim to discover these critical patient subsets. We propose a new technique designed specifically to find these interaction variables among a large set of variables while still controlling for the number of false discoveries. We compare this new method against standard qualitative interaction tests using simulations and give an example of its use on data from a randomized controlled trial for the treatment of depression.

Entities:  

Mesh:

Year:  2011        PMID: 22023676      PMCID: PMC3396291          DOI: 10.1080/10543406.2011.608052

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  20 in total

Review 1.  Moving towards individualized medicine with pharmacogenomics.

Authors:  William E Evans; Mary V Relling
Journal:  Nature       Date:  2004-05-27       Impact factor: 49.962

2.  Test for qualitative interaction in equivalence trials when the number of centres is large.

Authors:  Xin Yan
Journal:  Stat Med       Date:  2004-03-15       Impact factor: 2.373

3.  The challenge of subgroup analyses--reporting without distorting.

Authors:  Stephen W Lagakos
Journal:  N Engl J Med       Date:  2006-04-20       Impact factor: 91.245

4.  Selecting optimal treatment in clinical trials using covariate information.

Authors:  D P Byar; D K Corle
Journal:  J Chronic Dis       Date:  1977-07

5.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

6.  Subgroup analysis and other (mis)uses of baseline data in clinical trials.

Authors:  S F Assmann; S J Pocock; L E Enos; L E Kasten
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

7.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

8.  Naltrexone in the treatment of alcohol dependence.

Authors:  J H Krystal; J A Cramer; W F Krol; G F Kirk; R A Rosenheck
Journal:  N Engl J Med       Date:  2001-12-13       Impact factor: 91.245

9.  Interaction between prognostic factors and treatment.

Authors:  J Shuster; J van Eys
Journal:  Control Clin Trials       Date:  1983-09

10.  Tests against qualitative interaction: exact critical values and robust tests.

Authors:  M J Silvapulle
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

View more
  16 in total

1.  Optimizing delivery of a behavioral pain intervention in cancer patients using a sequential multiple assignment randomized trial SMART.

Authors:  Sarah A Kelleher; Caroline S Dorfman; Jen C Plumb Vilardaga; Catherine Majestic; Joseph Winger; Vicky Gandhi; Christine Nunez; Alyssa Van Denburg; Rebecca A Shelby; Shelby D Reed; Susan Murphy; Marie Davidian; Eric B Laber; Gretchen G Kimmick; Kelly W Westbrook; Amy P Abernethy; Tamara J Somers
Journal:  Contemp Clin Trials       Date:  2017-04-11       Impact factor: 2.226

2.  Generated effect modifiers (GEM's) in randomized clinical trials.

Authors:  Eva Petkova; Thaddeus Tarpey; Zhe Su; R Todd Ogden
Journal:  Biostatistics       Date:  2016-07-27       Impact factor: 5.899

3.  Evaluation of biomarkers for treatment selection using individual participant data from multiple clinical trials.

Authors:  Chaeryon Kang; Holly Janes; Parvin Tajik; Henk Groen; Ben Mol; Corine Koopmans; Kim Broekhuijsen; Eva Zwertbroek; Maria van Pampus; Maureen Franssen
Journal:  Stat Med       Date:  2018-02-14       Impact factor: 2.373

4.  A robust method for estimating optimal treatment regimes.

Authors:  Baqun Zhang; Anastasios A Tsiatis; Eric B Laber; Marie Davidian
Journal:  Biometrics       Date:  2012-05-02       Impact factor: 2.571

5.  A single-index model with a surface-link for optimizing individualized dose rules.

Authors:  Hyung Park; Eva Petkova; Thaddeus Tarpey; R Todd Ogden
Journal:  J Comput Graph Stat       Date:  2021-06-21       Impact factor: 1.884

6.  Combining biomarkers to optimize patient treatment recommendations.

Authors:  Chaeryon Kang; Holly Janes; Ying Huang
Journal:  Biometrics       Date:  2014-05-30       Impact factor: 2.571

7.  An approach to evaluating and comparing biomarkers for patient treatment selection.

Authors:  Holly Janes; Marshall D Brown; Ying Huang; Margaret S Pepe
Journal:  Int J Biostat       Date:  2014       Impact factor: 0.968

8.  Case-only approach to identifying markers predicting treatment effects on the relative risk scale.

Authors:  James Y Dai; C Jason Liang; Michael LeBlanc; Ross L Prentice; Holly Janes
Journal:  Biometrics       Date:  2017-09-28       Impact factor: 2.571

9.  The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration.

Authors:  David M Kent; David van Klaveren; Jessica K Paulus; Ralph D'Agostino; Steve Goodman; Rodney Hayward; John P A Ioannidis; Bray Patrick-Lake; Sally Morton; Michael Pencina; Gowri Raman; Joseph S Ross; Harry P Selker; Ravi Varadhan; Andrew Vickers; John B Wong; Ewout W Steyerberg
Journal:  Ann Intern Med       Date:  2019-11-12       Impact factor: 25.391

10.  Evaluating the Effectiveness of Personalized Medicine With Software.

Authors:  Adam Kapelner; Justin Bleich; Alina Levine; Zachary D Cohen; Robert J DeRubeis; Richard Berk
Journal:  Front Big Data       Date:  2021-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.